What are the open and close dates of the Nephrocare Health Services IPO ?

Nephrocare Health Services IPO will be open between 2025-12-10 and 2025-12-12.

What is the allotment date for the Nephrocare Health Services IPO ?

Nephrocare Health Services IPO allotment date is 2025-12-16. For Nephrocare Health Services IPO allotment status check, you can visit the website of the registrar of the IPO.

Who is the registrar of Nephrocare Health Services IPO ?

For Nephrocare Health Services IPO, the IPO registrar is KFin Technologies Limited . You can check Nephrocare Health Services IPO allotment status on the website of the registrar.

Where is the Nephrocare Health Services IPO getting listed?

The shares are proposed to be listed on the BSE and NSE.

When will Nephrocare Health Services IPO shares be credited to your demat account?

The Nephrocare Health Services IPO shares will typically be credited to your demat account one working day before the IPO's listing date, provided your application is successfully allotted.

What is the lot size and minimum order quantity of the Nephrocare Health Services IPO ?

The Nephrocare Health Services IPO lot size is 32 and minimum order quantity is 32.

What is the price band for the Nephrocare Health Services IPO ?

Nephrocare Health Services IPO has set the price band for its IPO at 460 per equity share with a face value of 2.

Home
/
IPO

13.82x

subscribed

Nephrocare Health Services IPO

Hospital & Healthcare Services

listed

₹14,016Min. investment

Pre-apply
8 Dec
Bid start
10 Dec
Bid end
12 Dec
Allotment
15 Dec
Release of funds
16 Dec
Demat transfer
16 Dec
Listing
17 Dec

Nephrocare Health Services Limited IPO Details

Issue size

₹871Cr

IPO type

Mainboard

Market Cap

₹4,615CrLower than sector avg

Price range

₹438 – ₹460

Listing ExchangeBSE, NSE

RevenueApr 2024 - Mar 2025

₹755.81CrLower than sector avg

Lot size

32 shares

Red Herring Prospectus

Read

Growth rate3Y CAGR

31.47%

SectorHospital & Healthcare Services

Price range₹438 – ₹460

IPO type

Regular

Lot size32 shares

Issue size₹871Cr

Red Herring Prospectus

Read

Market Cap

₹4,615CrLower than sector avg

RevenueApr 2024 - Mar 2025

₹755.81CrLower than sector avg

Growth rate3Y CAGR

31.47%

Nephrocare Health Services Limited IPO Overview

Nephrocare Health Services Innovations Limited IPO date

Nephrocare Health Services Innovations Limited IPO will open for subscription on December 10, 2025, and the closing date for the IPO is December 12, 2025. After this, investors are expected to be updated about the allotment status on December 15, 2025.

Investors who have been allotted shares can expect them to be credited to their demat account on December 16, 2025. The shares will be listed on the NSE and the BSE on Wednesday, December 17, 2025.

Nephrocare Health Services Innovations Limited IPO price band

The IPO includes a fresh issue and an offer for sale. The IPO price band has been set between ₹438 to ₹460 per share. Interested investors can choose a price within this band to apply for the IPO.

The IPO is a book-building issue, comprising a fresh issue of ₹353.40 crore and an offer for sale of ₹517.64 crore. Nephrocare Health Services Innovations Limited IPO listing price will be determined on December 17, 2025. The listing price is the price at which a company’s shares debut on the stock exchanges.

Nephrocare Health Services Innovations Limited IPO lot size

Nephrocare Health Services Innovations Limited IPO details have been declared. The minimum lot size for an application is 32 shares, and the investor would have to apply for a minimum of 1 lot. Meanwhile, the IPO issue size is approximately ₹871.05 crore.

Checklist

Quality analysis

Revenue growth

Company valuation

Earnings expansion

Risk analysis

Debt to Equity ratio

Promoter holdings

Shares pledged

The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily

Compare

Companies in this sector

Apollo Hospitals Enterprise Ltd

Max Healthcare Institute Ltd

Fortis Healthcare Ltd

Revenue

Higher revenue means strong sales and good market demand

This IPO

₹755.81Cr

This sector

₹810.55Cr

Compare with companies

PAT

Higher PAT means strong profitability and efficient cost management

This IPO

₹67.1Cr

This sector

₹87.66Cr

Compare with companies

Market cap

Higher market cap means strong confidence but may suggest overvaluation

This IPO

₹4,615Cr

This sector

₹10,075.9Cr

Compare with companies

P/E ratio

Lower ratio usually means stock is undervalued

This IPO

55.56

This sector

55.14

Compare with companies

D/E ratio

Lower ratio usually means fewer liabilities

This IPO

0.39

This sector

0.40

Compare with companies

Objectives

Repayment of borrowings

38.40%

Capital expenditure

36.50%

General corporate purposes

24.90%

Strength and Weakness

Largest dialysis chain with market leadership

The company is the largest dialysis service provider in India and Asia in FY25, with its scale being 4.4x bigger than the next largest Indian organised provider by operating revenue in FY24. It holds over 50% market share of the organised dialysis market in India in terms of both treatments and revenue, and ranks 5th globally by treatments in FY25. Its network delivered 18.7 lakhs treatments as of September 30, 2025 and spans 21 States + 4 UTs with 77.35% of clinics in Tier II/III cities.

Asset-light model delivering operational efficiency

The company has scaled from one clinic (2010) to 519 clinics across 328 cities by Sept 30, 2025, through greenfield, brownfield and PPP modes, with 52.41% clinics under revenue-sharing, reducing capital intensity. Its initiatives towards reducing capital expenditure include standardised clinic formats, an in-house projects team, and an efficient supply chain.

Proven track record of international expansion

It is the only Indian dialysis chain with international scale, generating 31.79% of revenue from overseas markets in FY25 versus 11.70% in FY23. In the Philippines, the company acquired 18 entities and expanded to 41 clinics serving 2,276 patients by September 30, 2025, while it also operates in Uzbekistan and Nepal. A USD 75+ million PPP tender in Uzbekistan includes the world’s largest 165-bed dialysis clinic, anchoring a long-term contracted business stream.

Clinical excellence driven by proprietary protocols

The company’s standardised RenAssure protocols and a strong advisory team ensure quality and patient safety, complemented by a registered ethics committee and involvement in 5 clinical trials as of September 2025. Proprietary technology such as Renova cloud-enabled dialyser reprocessing and mobile/clinical apps improves patient engagement and monitoring. The Enpidia academy (BONENT-accredited) has built a skilled workforce with 357 trained technicians deployed across clinics.

About Nephrocare Health Services Limited

Nephrocare Health Services Limited, operating under the brand ‘NephroPlus’, is India’s largest dialysis services provider in terms of the number of patients served, clinics, cities covered, treatments performed, revenue, and EBITDA in FY25.

The company serviced 29,281 patients and performed 2,885,450 treatments in India in FY25, representing roughly 10% of the country’s dialysis patient population. It is 4.40 times larger in size compared to the next biggest organised player in India in FY24 and also ranks as Asia’s largest and the 5th-largest globally by treatments performed in FY25.

Nephrocare Health Services operates a scaled global network of 519 clinics, including 51 international clinics across the Philippines, Uzbekistan, and Nepal as of September 30, 2025. It continues to have the most extensive presence in India, with clinics spread over 288 cities in 21 states and four union territories. Notably, 77.35% of its clinics are located in tier II and tier III cities, addressing care accessibility gaps where dialysis infrastructure is limited. The company has adopted an asset-light model in order to scale up both speedily and efficiently. As of September 30, 2025, 52.41% of its clinics operate on a revenue-sharing model that minimises upfront capital deployment. Its expansion is diversified across greenfield-which consists of 80 clinics, brownfield-259 clinics, and PPP collaborations-180 clinics, thus enabling faster rollouts and deeper penetration.

It is also the only Indian dialysis chain with proven international scalability because of its diversification strategy. International revenue contributed 31.79% of revenues in FY25, up from 11.70% in FY23, demonstrating successful market expansion into higher-realisation geographies. Acquisition-led growth in the Philippines and a $75+ million PPP project in Uzbekistan have showcased execution capabilities in competitive global markets.

As of September 30, 2025, the company operated 489 nephrologists and 1,754 clinical staff, ensuring robust medical oversight across its network. Off-clinic modalities such as home haemodialysis, dialysis-on-call across 11 pin code, and dialysis-on-wheels extend care access for patients unable to frequent hospitals. It also runs eight Enpidia training academies, the only BONENT-accredited dialysis technician institute in India, enabling a consistent talent pipeline and care standardisation at scale. The services provided by the company are differentiated through high-quality, standardised clinical care enabled by its proprietary RenAssure clinical protocols and a strong focus on patient experience. Three clinics were JCI-accredited, and 145 clinics were NABH-accredited as of September 30, 2025, demonstrating adherence to global healthcare quality standards. Its cloud-enabled, patented Renova reprocessing technology further supports consistency and safety at scale.

The global dialysis services market was valued at $75.2 billion in 2024 and is expected to reach $106.2 billion by 2029, growing at a CAGR of 7.10%. The company is focusing on high-growth international markets. In India, the dialysis industry is expected to grow at 19.30%, in the Philippines at 22.60%, and in Uzbekistan at 16.70%. As of September 30, 2025, the company has opened 51 clinics and has expanded into the Philippines, Uzbekistan, and Saudi Arabia since 2020. Furthermore, the formalisation of the dialysis market in India is noteworthy, which is estimated to grow at a higher rate compared to the unorganised market between 2024 and 2024 at 22.00% versus 19.00%. Furthermore, the number of ESRD patients is increasing at a CAGR of 12.70%, which strongly supports the growth of the business.

The company continues to focus on consolidating its leadership position in India, scaling operations in existing international markets, expanding further in South East Asia, the Commonwealth of Independent States and the Middle East markets and continuing to focus on innovation-led digital healthcare.

Now, Nephrocare Health Services Innovations is launching its initial public offering (IPO), which consists of a fresh issue of ₹353.40 crore and an offer for sale of ₹517.64 crore. The total issue size of the IPO is ₹871.05 crore. Its shares will be listed on the NSE and BSE.

How to pre-apply for the Nephrocare Health Services IPO?

You can pre-apply for the Nephrocare Health Services IPO on Upstox. The pre-application for this IPO, which means the pre-apply open date, usually begins a day before the IPO opens for subscription.

Follow these steps to pre-apply for the IPO:

Login to your Upstox account, using your six-digit PIN
After successfully logging in, click on ‘Discover’
On the Discover tab, you will find the ‘Invest in IPO’ section
Under the Invest in IPO section, look for the ‘Nephrocare Health Services IPO’ tab and click on it
Now fill in all the required information, like ‘bid price’ and ‘lot size’
Confirm and click on ‘Pre-Apply’
Accept the mandate on your UPI app

How to apply for the Nephrocare Health Services IPO?

If you are interested in this investment opportunity but unsure how to apply for the Nephrocare Health Services IPO, here are the steps that you need to follow.

When the public issue opens for subscription, one can follow this step-by-step guide on how to apply for the Nephrocare Health Services IPO on Upstox:

Log in to your Upstox account, using your six-digit PIN
After logging in, click on ‘Discover’
On the ‘Discover’ tab, you will find the ‘Invest in IPO’ section
Under the Invest in IPO section, look for the ‘Nephrocare Health Services IPO’ tab and click on it
Now fill in all the required information, like ‘bid price’ and ‘lot size’
Confirm and click on ‘Apply’
Accept the mandate on your UPI app

How to check Nephrocare Health Services IPO Allotment Status?

When the allotment process is completed, you can check the status of your application on the Upstox app. Share allotment is generally completed on the next working day after an IPO closes.

Here’s a step-by-step guide on how to check the Nephrocare Health Services IPO allotment status:

Login to your Upstox account, using your six-digit PIN
After logging in, click on ‘Discover’
On the ‘Discover’ page, you will find the ‘Invest in IPO’ section
Under the Invest in IPO section, you will find the ‘View all’ option
Once you click on ‘View all’, you will be directed to the ‘IPO’ tab
In the ‘IPO’ tab, click on ‘My applications’
In ‘My applications’, under the History section, your Nephrocare Health Services IPO allotment status will be mentioned

IPO Analysis

IPO REVIEW

Nephrocare Health Services IPO | Analysis Video

Nephrocare Health Services IPO

Should you apply?

View Video